Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA

Polychronis Pavlidis, Zakera Shums, Andreas L. Koutsoumpas, Jay Milo, M. Papp, Takeji Umemura, P. Lakatos, Daniel S. Smyk, Dimitrios P. Bogdanos, Alastair Forbes, Gary L. Norman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: We developed a new IgA and IgG anti-MZGP2 antibody ELISAs based on recombinant isoform-4 of human zymogen granule protein-2 (GP2), which is the major autoantigen of Crohn's disease (CrD)-specific pancreatic autoantibodies and assessed their clinical relevance in the largest inflammatory bowel disease (IBD) cohort tested to date. Methods: 832 sera were studied, including 617 consecutive IBD patients from 323 CrD and 294 ulcerative colitis (UC) follow-up in a tertiary centre, and 112 pathological and 103 normal controls. Results: Sensitivity of IgA anti-MZGP2 for CrD in the IBD population was 15% and specificity was 98% (95, 99), while the sensitivity and specificity of IgG anti-MZGP2 were 27% and 97%. IgA and IgG anti-MZGP2 combined testing led to a sensitivity of 31% and a specificity of 96%. Positivity for either ASCA (IgA or IgG) or anti-MZGP2 (IgA or IgG) showed a sensitivity of 75% (70, 80) and a specificity of 84% (79, 89). IgA anti-MZGP2 antibodies were more prevalent in CrD patients with early disease onset (p. =. 0.011). Also, anti-MZGP2 positive patients more frequently had extensive disease with ileal involvement. Patients with longer disease duration were more likely to have IgG anti-MZGP2 antibodies. Conclusions: Our novel ELISA confirms the high specificity of anti-MZGP2 antibodies for CrD and their association with disease severity phenotypes.

Original languageEnglish
Pages (from-to)176-181
Number of pages6
JournalClinica Chimica Acta
Volume441
DOIs
Publication statusPublished - Feb 4 2015

Fingerprint

Crohn Disease
Enzyme-Linked Immunosorbent Assay
Anti-Idiotypic Antibodies
Inflammatory Bowel Diseases
Antibodies
Immunoglobulin A
Immunoglobulin G
Ileal Diseases
Autoantigens
Secretory Vesicles
Ulcerative Colitis
Autoantibodies
Protein Isoforms
Phenotype
Sensitivity and Specificity
Enzyme Precursors
Serum
Population
anti-IgG
anti-IgA

Keywords

  • Autoantibody
  • Bowel disease
  • Marker
  • Sensitivity
  • Specificity

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA. / Pavlidis, Polychronis; Shums, Zakera; Koutsoumpas, Andreas L.; Milo, Jay; Papp, M.; Umemura, Takeji; Lakatos, P.; Smyk, Daniel S.; Bogdanos, Dimitrios P.; Forbes, Alastair; Norman, Gary L.

In: Clinica Chimica Acta, Vol. 441, 04.02.2015, p. 176-181.

Research output: Contribution to journalArticle

Pavlidis, P, Shums, Z, Koutsoumpas, AL, Milo, J, Papp, M, Umemura, T, Lakatos, P, Smyk, DS, Bogdanos, DP, Forbes, A & Norman, GL 2015, 'Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA', Clinica Chimica Acta, vol. 441, pp. 176-181. https://doi.org/10.1016/j.cca.2014.12.010
Pavlidis, Polychronis ; Shums, Zakera ; Koutsoumpas, Andreas L. ; Milo, Jay ; Papp, M. ; Umemura, Takeji ; Lakatos, P. ; Smyk, Daniel S. ; Bogdanos, Dimitrios P. ; Forbes, Alastair ; Norman, Gary L. / Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA. In: Clinica Chimica Acta. 2015 ; Vol. 441. pp. 176-181.
@article{9149d9214fbd41769a548f1bada438e5,
title = "Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA",
abstract = "Background: We developed a new IgA and IgG anti-MZGP2 antibody ELISAs based on recombinant isoform-4 of human zymogen granule protein-2 (GP2), which is the major autoantigen of Crohn's disease (CrD)-specific pancreatic autoantibodies and assessed their clinical relevance in the largest inflammatory bowel disease (IBD) cohort tested to date. Methods: 832 sera were studied, including 617 consecutive IBD patients from 323 CrD and 294 ulcerative colitis (UC) follow-up in a tertiary centre, and 112 pathological and 103 normal controls. Results: Sensitivity of IgA anti-MZGP2 for CrD in the IBD population was 15{\%} and specificity was 98{\%} (95, 99), while the sensitivity and specificity of IgG anti-MZGP2 were 27{\%} and 97{\%}. IgA and IgG anti-MZGP2 combined testing led to a sensitivity of 31{\%} and a specificity of 96{\%}. Positivity for either ASCA (IgA or IgG) or anti-MZGP2 (IgA or IgG) showed a sensitivity of 75{\%} (70, 80) and a specificity of 84{\%} (79, 89). IgA anti-MZGP2 antibodies were more prevalent in CrD patients with early disease onset (p. =. 0.011). Also, anti-MZGP2 positive patients more frequently had extensive disease with ileal involvement. Patients with longer disease duration were more likely to have IgG anti-MZGP2 antibodies. Conclusions: Our novel ELISA confirms the high specificity of anti-MZGP2 antibodies for CrD and their association with disease severity phenotypes.",
keywords = "Autoantibody, Bowel disease, Marker, Sensitivity, Specificity",
author = "Polychronis Pavlidis and Zakera Shums and Koutsoumpas, {Andreas L.} and Jay Milo and M. Papp and Takeji Umemura and P. Lakatos and Smyk, {Daniel S.} and Bogdanos, {Dimitrios P.} and Alastair Forbes and Norman, {Gary L.}",
year = "2015",
month = "2",
day = "4",
doi = "10.1016/j.cca.2014.12.010",
language = "English",
volume = "441",
pages = "176--181",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA

AU - Pavlidis, Polychronis

AU - Shums, Zakera

AU - Koutsoumpas, Andreas L.

AU - Milo, Jay

AU - Papp, M.

AU - Umemura, Takeji

AU - Lakatos, P.

AU - Smyk, Daniel S.

AU - Bogdanos, Dimitrios P.

AU - Forbes, Alastair

AU - Norman, Gary L.

PY - 2015/2/4

Y1 - 2015/2/4

N2 - Background: We developed a new IgA and IgG anti-MZGP2 antibody ELISAs based on recombinant isoform-4 of human zymogen granule protein-2 (GP2), which is the major autoantigen of Crohn's disease (CrD)-specific pancreatic autoantibodies and assessed their clinical relevance in the largest inflammatory bowel disease (IBD) cohort tested to date. Methods: 832 sera were studied, including 617 consecutive IBD patients from 323 CrD and 294 ulcerative colitis (UC) follow-up in a tertiary centre, and 112 pathological and 103 normal controls. Results: Sensitivity of IgA anti-MZGP2 for CrD in the IBD population was 15% and specificity was 98% (95, 99), while the sensitivity and specificity of IgG anti-MZGP2 were 27% and 97%. IgA and IgG anti-MZGP2 combined testing led to a sensitivity of 31% and a specificity of 96%. Positivity for either ASCA (IgA or IgG) or anti-MZGP2 (IgA or IgG) showed a sensitivity of 75% (70, 80) and a specificity of 84% (79, 89). IgA anti-MZGP2 antibodies were more prevalent in CrD patients with early disease onset (p. =. 0.011). Also, anti-MZGP2 positive patients more frequently had extensive disease with ileal involvement. Patients with longer disease duration were more likely to have IgG anti-MZGP2 antibodies. Conclusions: Our novel ELISA confirms the high specificity of anti-MZGP2 antibodies for CrD and their association with disease severity phenotypes.

AB - Background: We developed a new IgA and IgG anti-MZGP2 antibody ELISAs based on recombinant isoform-4 of human zymogen granule protein-2 (GP2), which is the major autoantigen of Crohn's disease (CrD)-specific pancreatic autoantibodies and assessed their clinical relevance in the largest inflammatory bowel disease (IBD) cohort tested to date. Methods: 832 sera were studied, including 617 consecutive IBD patients from 323 CrD and 294 ulcerative colitis (UC) follow-up in a tertiary centre, and 112 pathological and 103 normal controls. Results: Sensitivity of IgA anti-MZGP2 for CrD in the IBD population was 15% and specificity was 98% (95, 99), while the sensitivity and specificity of IgG anti-MZGP2 were 27% and 97%. IgA and IgG anti-MZGP2 combined testing led to a sensitivity of 31% and a specificity of 96%. Positivity for either ASCA (IgA or IgG) or anti-MZGP2 (IgA or IgG) showed a sensitivity of 75% (70, 80) and a specificity of 84% (79, 89). IgA anti-MZGP2 antibodies were more prevalent in CrD patients with early disease onset (p. =. 0.011). Also, anti-MZGP2 positive patients more frequently had extensive disease with ileal involvement. Patients with longer disease duration were more likely to have IgG anti-MZGP2 antibodies. Conclusions: Our novel ELISA confirms the high specificity of anti-MZGP2 antibodies for CrD and their association with disease severity phenotypes.

KW - Autoantibody

KW - Bowel disease

KW - Marker

KW - Sensitivity

KW - Specificity

UR - http://www.scopus.com/inward/record.url?scp=84921515346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921515346&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2014.12.010

DO - 10.1016/j.cca.2014.12.010

M3 - Article

C2 - 25512163

AN - SCOPUS:84921515346

VL - 441

SP - 176

EP - 181

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -